008 |
|
200616s2020 si a ob 000 0 eng d |
020 |
|
|a9789811456916|q(electronic bk.)
|
020 |
|
|a9811456917|q(electronic bk.)
|
020 |
|
|z9789811456893|q(print)
|
020 |
|
|z9789811456909|q(pbk.)
|
040 |
|
|aYDX|beng|cYDX|dN|T|dOCLCO|dEBLCP|dOCLCF|dOCLCQ|dUKAHL
|
050 |
4
|
|aR857.N34
|
082 |
04
|
|a610.28|223
|
245 |
00
|
|aAdvances in cancer nanotheranostics for experimental and personalized medicine|h[electronic resource] /|cedited by Yusuf Tutaru.
|
250 |
|
|a1st ed.
|
260 |
|
|aSingapore :|bBentham Science Publishers,|cc2020.
|
300 |
|
|a1 online resource :|bcol. ill.
|
504 |
|
|aIncludes bibliographical references.
|
520 |
|
|aNanotheranostics is a recent medical field which integrates diagnostic imaging protocols and therapeutic functions to monitor real time drug release in the body and distribution to the target site. The combined processes allow technicians to observe the effectiveness of a specifically designed drug candidate and predict its possible side effects. All these features help clinicians in optimizing treatment options for cancer and other diseases for the individual patient. Current research is tailored to individual therapy because each drug may display a variety of responses depending on variation.
|
588 |
|
|aDescription based on print version record.
|
650 |
0
|
|aNanomedicine.
|
650 |
0
|
|aNanostructured materials.
|
700 |
1
|
|aTutaru, Yusuf.
|
856 |
40
|
|uhttps://www.eurekaselect.com/166842/volume1
|